HOOKIPA Pharma prices $50M public offering of common & convertible preferred stock

HOOKIPA Pharma Inc.

Priced 22,900,768 shares of common stock at $1.31/share and 15,268 Series A-2 convertible preferred shares at $1,310/share.
Gross proceeds of $50M; net proceeds expected ~$46.3M after underwriting discounts and expenses.
Offering expected to close June 5, 2023; joint book-runners are SVB Securities and RBC Capital Markets.
Each Series A-2 preferred share converts into 1,000 common shares, non-voting, with a beneficial ownership cap of 9.99%.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

HOOKIPA Pharma Inc.: Filed Certificate of Designation creating Series A-2 Convertible Preferred Stock (effective 2023-06-01).

Change: charter amendment
Effective: 2023-06-01

Exact text from the filing

On June 1, 2023, the Company filed a Certificate of Designation of Series A-2 Convertible Preferred Stock with the Delaware Secretary of State

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

HOOKIPA Pharma Inc. entered into Underwriting Agreement with SVB Securities LLC and RBC Capital Markets, LLC valued at $46.3 million (effective 2023-05-31).

Action: entry
Agreement: underwriting
Counterparty: SVB Securities LLC and RBC Capital Markets, LLC
Value: $46.3 million
Effective: 2023-05-31

Exact text from the filing

On May 31, 2023, HOOKIPA Pharma Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the underwriters listed on Schedule A thereto

View on SEC.gov

Browse all governance changes →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-067170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.